Skip to main content

News

Early GI Involvement Predictive of Scleroderma Outcomes

Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).

Hydroxychloroquine: 5 mg/kg/day Is Only the Starting Point

Hydroxychloroquine (HCQ) is one of the most important drugs in rheumatology, especially for systemic lupus erythematosus (SLE). It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival.

Immune-Mediated Inflammatory Diseases Following Uveitis

A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).

Does Exercise and Lifestyle Modification Improve RA?

Does exercise or lifestyle modifications reduce the risk of getting rheumatoid arthritis (RA) or change those with early RA?

ABA versus HCQ in Palindromic Rheumatism

Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study. 

Update on Multicentric Reticulohistiocytosis

Have you ever seen multicentric reticulohistiocytosis? Don't worry, it's a rare non-Langerhans cell histiocytosis condition, characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and has only been described in fewer than 500 cases reported worldwide.

Infectious Rheumatology (5.15.2026)

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.

Fatigue in SLE

An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.

Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis

Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and

EGPA Review

A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.

Toll-Like Receptor Drugs Effective in Cutaneous Lupus

MedPage Today
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.

Lupus Mortality Risk in Young Women

ACR

New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant and often underrecognized public health burden.

×